Biogen Investors Face Next Test in Gamble on Alzheimer’s Disease

(Bloomberg) -- Investors betting on Biogen Inc.’s back-from-the-dead Alzheimer’s drug are approaching a key hurdle in a wild saga that has already spanned nearly a year.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.